Ekso Bionics Holdings, Inc. (EKSO) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Biomerica, Inc.

bioAffinity Technologies, Inc.

Venus Concept, Inc.

Ekso Bionics Holdings, Inc.

Prosomnus, Inc.

Ainos, Inc.

Predictive Oncology, Inc.

Talis Biomedical Corp.

BioRestorative Therapies, Inc.

Nemaura Medical, Inc.

MedAvail Holdings, Inc.

Why is Ekso Bionics Holdings, Inc. ?

Poor long term growth as Operating profit has grown by an annual rate 2.45% of over the last 5 years

The company has declared negative results in Mar'2025 after 3 consecutive positive quarters

NET SALES(HY) At USD 6.28 MM has Grown at -30.79%
ROCE(HY) Lowest at -85.01%
CASH AND EQV(HY) Lowest at USD 7.96 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 43.15%, its profits have risen by 6%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Ekso Bionics Holdings, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Ekso Bionics Holdings, Inc.

49.69%

0.59

1454.88%

S&P 500

13.68%

0.71

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

7.34%

EBIT Growth (5y)

2.45%

EBIT to Interest (avg)

-13.29

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.22

Sales to Capital Employed (avg)

0.90

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

20.96%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.11

EV to EBIT

-3.78

EV to EBITDA

-4.39

EV to Capital Employed

3.58

EV to Sales

2.83

PEG Ratio

Dividend Yield

ROCE (Latest)

-94.62%

ROE (Latest)

-108.16%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

12What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -8.89 MM

RAW MATERIAL COST(Y)

Fallen by -12.95% (YoY

OPERATING PROFIT(Q)

Highest at USD -1.03 MM

OPERATING PROFIT MARGIN(Q)

Highest at -24.49 %

PRE-TAX PROFIT(Q)

Highest at USD -1.42 MM

NET PROFIT(Q)

Highest at USD -1.42 MM

EPS(Q)

Highest at USD -0.54

-13What is not working for the Company

NET SALES(HY)

At USD 6.28 MM has Grown at -30.79%

ROCE(HY)

Lowest at -85.01%

CASH AND EQV(HY)

Lowest at USD 7.96 MM

DEBT-EQUITY RATIO (HY)

Highest at 23.07 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.36 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.27 times

Here's what is working for Ekso Bionics Holdings, Inc.

Operating Cash Flow

Highest at USD -8.89 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Operating Profit

Highest at USD -1.03 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin

Highest at -24.49 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at USD -1.42 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD -1.42 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD -0.54

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost

Fallen by -12.95% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Ekso Bionics Holdings, Inc.

Net Sales

At USD 6.28 MM has Grown at -30.79%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Cash and Eqv

Lowest at USD 7.96 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at 23.07 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 1.36 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio

Lowest at 2.27 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio